155 related articles for article (PubMed ID: 20722752)
1. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Hansen AB; Obel N; Nielsen H; Pedersen C; Gerstoft J
HIV Med; 2011 Mar; 12(3):157-65. PubMed ID: 20722752
[TBL] [Abstract][Full Text] [Related]
2. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Rivas P; Górgolas M; García-Delgado R; Díaz-Curiel M; Goyenechea A; Fernández-Guerrero ML
HIV Med; 2008 Feb; 9(2):89-95. PubMed ID: 18093130
[TBL] [Abstract][Full Text] [Related]
3. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
[TBL] [Abstract][Full Text] [Related]
4. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
5. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
6. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
Fraaij PL; Neubert J; Bergshoeff AS; van Rossum AM; Hartwig NG; Schroten H; Korn K; Burger DM; de Groot R; Niehues T
Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193
[TBL] [Abstract][Full Text] [Related]
9. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Haubrich RH; Riddler SA; DiRienzo AG; Komarow L; Powderly WG; Klingman K; Garren KW; Butcher DL; Rooney JF; Haas DW; Mellors JW; Havlir DV;
AIDS; 2009 Jun; 23(9):1109-18. PubMed ID: 19417580
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
11. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
13. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
14. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
15. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
16. Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.
Crespo M; Navarro J; Martinez-Rebollar M; Podzamczer D; Domingo P; Mallolas J; Saumoy M; Mateo GM; Curran A; Gatell J; Ribera E
HIV Clin Trials; 2016 May; 17(3):89-95. PubMed ID: 27125363
[TBL] [Abstract][Full Text] [Related]
17. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
20. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
